KRAS and cancer: Multiple studies using RNAi (siRNA/shRNA) libraries targeting over 1000 genes in isogenic wild-type and mutant K-Ras cell lines [25,26] or different mutant K-Ras cell lines [27,28,29,35] identified genes selectively dependent on K-Ras function as potential therapeutic targets for cancers exhibiting aberrant K-Ras activity.